CureVac focuses on the development of mRNA-based coronavirus vaccine to protect people worldwide
TüBINGEN, Germany/ BOSTON – March 15, 2020 – CureVac AG, a clinical stage biopharmaceutical company pioneering mRNA-based drugs for vaccines and therapeutics, confirmed today that internal efforts are focused on the development of a coronavirus vaccine with the goal to reach, help and to protect people and patients worldwide.
As a consequence, the company is in contact with especially CEPI and many other organizations and authorities worldwide, however abstains from commenting on speculations and rejects allegations about offers for acquisition of the company or its technology.
Based on its inherent mode of action, CureVac sees mRNA as one of the most potent molecules to provide fast and efficient solutions in outbreak scenarios, such like the Coronavirus. With inhouse expertise of over two decades and the company’s deep scientific understanding CureVac is leveraging its potent vaccine platform to focus on developing a potent, efficacious and safe and fast to produce vaccine against Covid-19.
CureVac recently announced successful vaccination results in its Rabies program fully protecting humans with two doses of only 1 microgram (1 millionth of a gram). These results are encouraging when thinking of supplying populations and people worldwide in a pandemic scenario.
The company also has long and strong manufacturing expertise for mRNA-based vaccines and therapeutics since 2006. At this time, CureVac is working on expanding its manufacturing capacities to be able to provide up to billions of doses for outbreak situations like Covid-19.
Mariola Fotin-Mleczek, Chief Technology Officer of CureVac, commented: “ Nature has invented mechanisms to activate our immune system against infectious diseases. With our unique messenger RNA technology we mimic nature and give our body the information how to fight against the virus. The combination of mRNA science, disease understanding, formulation and production expertise make CureVac a unique player to fight against any infectious disease, no matter whether they are seasonal or pandemic.”
About CureVac AG
CureVac is a leading clinical stage biotechnology company in the field of messenger RNA (mRNA) technology with 20 years of expertise in developing and optimizing this versatile molecule for medical purposes. The principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. The company applies its technologies for the development of cancer therapies, antibody therapies, the treatment of rare diseases, and prophylactic vaccines. CureVac has received significant investments, amongst others from dievini Hopp BioTech holding and the Bill & Melinda Gates Foundation. CureVac has also entered into collaborations with multinational corporations and organizations, including CEPI, Boehringer Ingelheim, Eli Lilly & Co, Genmab, CRISPR Therapeutics, the Bill & Melinda Gates Foundation, and others. CureVac is headquartered in Tübingen, Germany with sites in Frankfurt and Boston, USA.
For more information, please visit www.curevac.com or follow us on Twitter at @CureVacAG.
CureVac Media Contact
Thorsten Schüller, Head of Corporate Communications
Key Points Recent improvements in mRNA vaccines act to increase protein translation, modulate innate and adaptive immunogenicity and improve delivery.
mRNA vaccines have elicited potent immunity against infectious disease targets in animal models of influenza virus, Zika virus, rabies virus and others, especially in recent years, using lipid-encapsulated or naked forms of sequence-optimized mRNA.
Diverse approaches to mRNA cancer vaccines, including dendritic cell vaccines and various types of directly injectable mRNA, have been employed in numerous cancer clinical trials, with some promising results showing antigen-specific T cell responses and prolonged disease-free survival in some cases.
Therapeutic considerations and challenges include scaling up good manufacturing practice (GMP) production, establishing regulations, further documenting safety and increasing efficacy.
Important future directions of research will be to compare and elucidate the immune pathways activated by various mRNA vaccine platforms, to improve current approaches based on these mechanisms and to initiate new clinical trials against additional disease targets.
Abstract mRNA vaccines represent a promising alternative to conventional vaccine approaches because of their high potency, capacity for rapid development and potential for low-cost manufacture and safe administration. However, their application has until recently been restricted by the instability and inefficient in vivo delivery of mRNA. Recent technological advances have now largely overcome these issues, and multiple mRNA vaccine platforms against infectious diseases and several types of cancer have demonstrated encouraging results in both animal models and humans. This Review provides a detailed overview of mRNA vaccines and considers future directions and challenges in advancing this promising vaccine platform to widespread therapeutic use.
就是前段时间德国媒体在传，说川普想过来花重金挖角科学家，甚至想购买这家公司专门给美国做疫苗的那家。
看到德国病毒学家Alexander Kekule接受广播电台采访的时候说，这是一种什么从分子层面产生蛋白质，然后以此为材料直接制作的疫苗，注入人体之后就能产生免疫作用。不同于目前传统的抗体疫苗开发方式，是一种比较现代甚至科幻的感觉。
而且世界上目前还没有以这种方法制作疫苗获准进入市场的先例。
有懂的千老说说靠谱不靠谱？
更新：刚才去谷歌了一下curevac，看到他们公司上门有很简要的介绍：https://www.curevac.com/news/curevac-focuses-on-the-development-of-mrna-
based-coronavirus-vaccine-to-protect-people-worldwide
什么mRNA的，是啥意思？
哇塞，好高端。从分子层面产生蛋白。
除了从分子层面产生，还能怎么产生啊。证屁轮子来解释解释。
分子层面这个说法我只在转发轮里见过，你这是轮比自己暴露了，哈哈
先不用笑，这是德国人说的
我不是生物专业，来问问这个靠不靠谱。
德国人自己也说有点科幻的味道。
不是这个专业，也没听说过这种方法的就不用乱喷了。
【 在 quovadis (My shit is your gourmet) 的大作中提到: 】
: 哇塞，好高端。从分子层面产生蛋白。
: 除了从分子层面产生，还能怎么产生啊。证屁轮子来解释解释。
除非这家德国公司会全合成蛋白抗原，就像人工全合成牛胰岛素一样
所以理论上并不是不可能的对吧？
德国人说美国也有几家公司在做这种疫苗。
但是德国有科学家有专利在手，所以特朗普来挖人。结果媒体捅出来了，左媒都反川，德国的也一样，这下抓着这件事情又狠狠黑了川普一把。
【 在 lubbock34 (胡汉三又回来了) 的大作中提到: 】
: 除非这家德国公司会全合成蛋白抗原，就像人工全合成牛胰岛素一样
不过德国化学合成和化工都很厉害，不是不可能
【 在 boilingsnow (沸腾的雪) 的大作中提到: 】
: 所以理论上并不是不可能的对吧？
: 德国人说美国也有几家公司在做这种疫苗。
: 但是德国有科学家有专利在手，所以特朗普来挖人。结果媒体捅出来了，左媒都反川，
: 德国的也一样，这下抓着这件事情又狠狠黑了川普一把。
疫苗开发这种事
主要大国都不可能在一棵树上吊死
谁也说不好哪家的疫苗最终有效
中国已经有公司和这家德国公司合作得到中国国内的授权
CureVac focuses on the development of mRNA-based coronavirus vaccine to
protect people worldwide
TüBINGEN, Germany/ BOSTON – March 15, 2020 – CureVac AG, a clinical stage biopharmaceutical company pioneering mRNA-based drugs for vaccines and
therapeutics, confirmed today that internal efforts are focused on the
development of a coronavirus vaccine with the goal to reach, help and to
protect people and patients worldwide.
As a consequence, the company is in contact with especially CEPI and many
other organizations and authorities worldwide, however abstains from
commenting on speculations and rejects allegations about offers for
acquisition of the company or its technology.
Based on its inherent mode of action, CureVac sees mRNA as one of the most
potent molecules to provide fast and efficient solutions in outbreak
scenarios, such like the Coronavirus. With inhouse expertise of over two
decades and the company’s deep scientific understanding CureVac is
leveraging its potent vaccine platform to focus on developing a potent,
efficacious and safe and fast to produce vaccine against Covid-19.
CureVac recently announced successful vaccination results in its Rabies
program fully protecting humans with two doses of only 1 microgram (1
millionth of a gram). These results are encouraging when thinking of
supplying populations and people worldwide in a pandemic scenario.
The company also has long and strong manufacturing expertise for mRNA-based vaccines and therapeutics since 2006. At this time, CureVac is working on
expanding its manufacturing capacities to be able to provide up to billions of doses for outbreak situations like Covid-19.
Mariola Fotin-Mleczek, Chief Technology Officer of CureVac, commented: “
Nature has invented mechanisms to activate our immune system against
infectious diseases. With our unique messenger RNA technology we mimic
nature and give our body the information how to fight against the virus. The combination of mRNA science, disease understanding, formulation and
production expertise make CureVac a unique player to fight against any
infectious disease, no matter whether they are seasonal or pandemic.”
About CureVac AG
CureVac is a leading clinical stage biotechnology company in the field of
messenger RNA (mRNA) technology with 20 years of expertise in developing and optimizing this versatile molecule for medical purposes. The principle of
CureVac's proprietary technology is the use of mRNA as a data carrier to
instruct the human body to produce its own proteins capable of fighting a
wide range of diseases. The company applies its technologies for the
development of cancer therapies, antibody therapies, the treatment of rare
diseases, and prophylactic vaccines. CureVac has received significant
investments, amongst others from dievini Hopp BioTech holding and the Bill & Melinda Gates Foundation. CureVac has also entered into collaborations with multinational corporations and organizations, including CEPI, Boehringer
Ingelheim, Eli Lilly & Co, Genmab, CRISPR Therapeutics, the Bill & Melinda
Gates Foundation, and others. CureVac is headquartered in Tübingen, Germany with sites in Frankfurt and Boston, USA.
For more information, please visit www.curevac.com or follow us on Twitter
at @CureVacAG.
CureVac Media Contact
Thorsten Schüller, Head of Corporate Communications
Tel: +49 (0)7071 9883-1577
Email: [email protected]
和Moderna类似吧，mRNA平台。
【 在 boilingsnow (沸腾的雪) 的大作中提到: 】
: 就是前段时间德国媒体在传，说川普想过来花重金挖角科学家，甚至想购买这家公司专
: 门给美国做疫苗的那家。
: 看到德国病毒学家Alexander Kekule接受广播电台采访的时候说，这是一种什么从分子
: 层面产生蛋白质，然后以此为材料直接制作的疫苗，注入人体之后就能产生免疫作用。
: 不同于目前传统的抗体疫苗开发方式，是一种比较现代甚至科幻的感觉。
: 而且世界上目前还没有以这种方法制作疫苗获准进入市场的先例。
: 有懂的千老说说靠谱不靠谱？
: 更新：刚才去谷歌了一下curevac，看到他们公司上门有很简要的介绍：
: https://www.curevac.com/news/curevac-focuses-on-the-development-of-mrna-
: based-coronavirus-vaccine-to-protect-people-worldwide
: ...................
到底能不能最后成功现在谁也不知道。没有强大的资金支持，做一系列开发和临床试验，得不到答案。美国在各种新技术早期投资很多，有最后成功的，也有很多失败的。
注资方获得全部或部分市场销售权，是最常见的合作和风险共担方式。现在别有用心的人把正常的商业运作炒作成反美的宣传，真是丧心病狂。实际上是美国想提供大部分资金，获得大部分市场销售权，中国市场由另外的公司获得。
curevac 当然可以不卖，没人逼着他卖，不卖curevac 就需要有足够资金，并承担所有风险，开发不成功就全部打水漂，立马破产。
往上搜的，mRNA疫苗和普通疫苗有啥区别？
mRNA vaccines — a new era in vaccinology
Key Points
Recent improvements in mRNA vaccines act to increase protein translation,
modulate innate and adaptive immunogenicity and improve delivery.
mRNA vaccines have elicited potent immunity against infectious disease
targets in animal models of influenza virus, Zika virus, rabies virus and
others, especially in recent years, using lipid-encapsulated or naked forms of sequence-optimized mRNA.
Diverse approaches to mRNA cancer vaccines, including dendritic cell
vaccines and various types of directly injectable mRNA, have been employed
in numerous cancer clinical trials, with some promising results showing
antigen-specific T cell responses and prolonged disease-free survival in
some cases.
Therapeutic considerations and challenges include scaling up good
manufacturing practice (GMP) production, establishing regulations, further
documenting safety and increasing efficacy.
Important future directions of research will be to compare and elucidate the immune pathways activated by various mRNA vaccine platforms, to improve
current approaches based on these mechanisms and to initiate new clinical
trials against additional disease targets.
Abstract
mRNA vaccines represent a promising alternative to conventional vaccine
approaches because of their high potency, capacity for rapid development and potential for low-cost manufacture and safe administration. However, their application has until recently been restricted by the instability and
inefficient in vivo delivery of mRNA. Recent technological advances have now largely overcome these issues, and multiple mRNA vaccine platforms against infectious diseases and several types of cancer have demonstrated
encouraging results in both animal models and humans. This Review provides a detailed overview of mRNA vaccines and considers future directions and
challenges in advancing this promising vaccine platform to widespread
therapeutic use.
德国联邦政府介入了，阻止了美方的要求。现在这种情况德国政府肯定会兜住，所以资金估计没有问题。
这个新闻也是德国政府里面的人爆出来的。
就是左媒想黑特朗普，煽动民粹。西方媒体整天干这个
【 在 goodby () 的大作中提到: 】
: 到底能不能最后成功现在谁也不知道。没有强大的资金支持，做一系列开发和临床试验
: ，得不到答案。美国在各种新技术早期投资很多，有最后成功的，也有很多失败的。: 注资方获得全部或部分市场销售权，是最常见的合作和风险共担方式。现在别有用心的
: 人把正常的商业运作炒作成反美的宣传，真是丧心病狂。实际上是美国想提供大部分资
: 金，获得大部分市场销售权，中国市场由另外的公司获得。
: curevac 当然可以不卖，没人逼着他卖，不卖curevac 就需要资金由足够资金，并承担
: 所有风险，开发不成功就全部打水漂，立马破产。
德国政府想兜底当然最好。很明显 Curevac 自己没有资金和实力完成开发和试验，在
市场上招资。本国政府有权利以国家安全为明，阻止并购或外方注资。
德国自己能开发出来最好不过了。看看现在德国鼓吹的欧盟开放和世界共享能否真正做到。从历史和最近发生的扣留邻国紧急医用物资来看，德国做不到为世界奉献。
【 在 boilingsnow (沸腾的雪) 的大作中提到: 】
: 德国联邦政府介入了，阻止了美方的要求。现在这种情况德国政府肯定会兜住，所以资
: 金估计没有问题。
: 这个新闻也是德国政府里面的人爆出来的。
: 就是左媒想黑特朗普，煽动民粹。西方媒体整天干这个
mRNA疫苗都不懂，不过对于轮子老酱来说要求太高了
这个西雅图也有，不过希望不大，容易被细胞分解，活性很低
还是跪求玄月给你们科普一下吧
你懂你给说说
美国人这不是想去德国买公司，挖人么
德国人比美国人高明在哪里？
你说得出来不？
【 在 Fallingrains (Fallingrains) 的大作中提到: 】
: mRNA疫苗都不懂，不过对于轮子老酱来说要求太高了
: 这个西雅图也有，不过希望不大，容易被细胞分解，活性很低
: 还是跪求玄月给你们科普一下吧
德国现在这个疫情情况，德国政府肯定会兜底。小几十亿欧元德国政府肯定会出。
现在这种情况，德国每个州都已经要出100亿欧元扶植各种小企业。
【 在 goodby () 的大作中提到: 】
: 德国政府想兜底当然最好。很明显 Curevac 自己没有资金和实力完成开发和试验，在
: 市场上招资。本国政府有权利以国家安全为明，阻止并购或外方注资。
: 德国自己能开发出来最好不过了。看看现在德国鼓吹的欧盟开放和世界共享能否真正做
: 到。从历史和最近发生的扣留邻国紧急医用物资来看，德国做不到为世界奉献。
看来你也不懂呀。
【 在 Fallingrains (Fallingrains) 的大作中提到: 】
: mRNA疫苗都不懂，不过对于轮子老酱来说要求太高了
: 这个西雅图也有，不过希望不大，容易被细胞分解，活性很低
: 还是跪求玄月给你们科普一下吧
欧洲白左早就十分讨厌川普了
【 在 boilingsnow (沸腾的雪) 的大作中提到: 】
: 德国联邦政府介入了，阻止了美方的要求。现在这种情况德国政府肯定会兜住，所以资
: 金估计没有问题。
: 这个新闻也是德国政府里面的人爆出来的。
: 就是左媒想黑特朗普，煽动民粹。西方媒体整天干这个